Shoreline Biosciences, a gene editing and cell therapy biotech, has let go of staffers dedicated to a cell therapy project ...
IGM Biosciences announced plans to stay afloat by focusing its resources on a clinical-stage autoimmune asset. Now it's ...
As Bayer awaits an FDA decision on its non-hormonal treatment for hot flashes caused by menopause, it's unveiling new results ...
Intellia Therapeutics is the latest CRISPR company resorting to layoffs as investors increasingly turn away from gene editing. The Cambridge, MA-based company announced Thursday that it would reduce ...
Catalyst Therapeutics' controversial, $375,000 rare autoimmune disease drug now won't face generic competition from Teva ...
A Dutch biotech creating nasal sprays to protect against the flu and coronavirus has raised an additional $70 ...
Versant Ventures' latest biotech emerged on Thursday morning with a $62 million Series A from Bristol Myers Squibb, AbbVie ...
A2 Biotherapeutics has raised $80 million to run three experimental CAR-T programs for solid tumor cancers. The ...
Biopharma leaders head to San Francisco's JP Morgan Healthcare Conference amid hopes for M&A deals after slow 2024, which saw ...
Sutro scale-up, Pharma mergers, FDA warnings to Indian firms, new Egypt facility, and UPS acquires Frigo-Trans ...
Novo Holdings co-leads €32M Series A for Coave Therapeutics, which is developing gene therapies with its ALIGATER technology.
H1 acquires Ribbon Health to expand doctor-patient connections. Ribbon serves about 25M patients yearly; H1 aims to reach ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback